TVThangavel Mahalingam Vijayakumar

Thangavel Mahalingam Vijayakumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thangavel Mahalingam Vijayakumar has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endothelial Dysfunction and Inflammatory Pathways in Heart Failure – Role of suPAR and sVCAM-1 as Novel Biomarkers

    by Gunanidhi Sakthivel, Vijayakumar Thangavel Mahalingam, Suryaprakash Sabapathi

    Introduction: Heart failure (HF) is a multifactorial clinical syndrome characterised by myocardial remodelling, endothelial dysfunction, and chronic inflammation. Emerging evidence highlights the role of inflammatory and endothelial biomarkers, particularly soluble urokinase plasminogen activator receptor (suPAR) and soluble vascular cell adhesion molecule-1 (sVCAM-1), in improving our understanding and management of HF. Methods: A narrative review of the literature was conducted to evaluate the biological significance, clinical utility, and prognostic relevance of suPAR and sVCAM-1 in HF. Given the heterogeneity of study designs, HF phenotypes, and clinical outcomes, the available evidence was critically synthesised to provide an integrated overview of these biomarkers. Results: Endothelial dysfunction and persistent inflammation were identified as key contributors to the pathogenesis of HF. Elevated suPAR levels are associated with immune activation, myocardial remodelling, renal dysfunction, increased rehospitalisation, and mortality. Similarly, increased sVCAM-1 concentrations reflect endothelial activation and vascular inflammation and are linked to adverse cardiac remodelling and poor clinical outcomes. Both biomarkers have potential value in early diagnosis, risk stratification, and therapeutic monitoring, particularly in patients with heart failure with preserved ejection fraction (HFpEF). Discussion: suPAR and sVCAM-1 provide complementary information beyond that of conventional natriuretic peptides by capturing the inflammatory and endothelial mechanisms involved in HF progression. The incorporation of these markers into multi-marker strategies may improve risk assessment and support personalised treatment approaches. Conclusion: suPAR and sVCAM-1 are promising biomarkers for enhancing diagnosis, prognostic assessment, and therapeutic monitoring in HF. Further multicentre prospective studies are needed to validate their clinical utility and establish their roles in precision heart failure management.

  • Effects of piperine–haloperidol mixture on ketamine induced schizophrenia rats and metabolism-mediated inhibitory potency: in-vivo and in-vitro evaluation

    by B. R. Pradeepa, T. M. Vijayakumar, K. Manikandan

    Haloperidol, a conventional antipsychotic, was mixed with piperine in a ketamine-induced schizophrenia rat model to evaluate the interaction potential of this mixture through in-vitro and in-vivo analyses. Piperine, known for its CYP450 enzyme inhibitory effects, enhances the bioavailability of various drugs. Initial in-vitro assays using a high-throughput fluorometric method showed that the haloperidol–piperine mixture inhibited CYP3A4 and CYP2D6 enzymes, comparable to positive controls. In-vivo pharmacokinetic results revealed that piperine significantly increased haloperidol’s plasma concentration and area under the curve while reducing clearance, indicating enhanced bioavailability. Pharmacodynamic assessments showed reductions in locomotor activity, immobility time, dopamine levels, and nitric oxide, with increased superoxide dismutase levels in the haloperidol–piperine group compared to haloperidol alone, reflecting enhanced therapeutic efficacy. These findings indicate that piperine can increase haloperidol exposure, potentially allowing for dose reduction and minimizing dose-related side effects. Limitations of this study include reliance on a rat model, which may not fully replicate human metabolism, and lack of long-term safety assessment. Future studies should explore the clinical applicability of this mixture in human trials, particularly focusing on safety, dosage optimization, and long-term effects. Additionally, understanding piperine’s role in different metabolic pathways could guide the development of targeted bioavailability enhancers, improving efficacy for a range of CYP450-metabolized medications.

  • Open Access

    CYP2C19 polymorphisms on escitalopram treatment outcome in South Indian population with major depressive disorder

    by B Jeevan Kumar, Vijayakumar Thangavel Mahalingam, Ganesh Kumar

    Various CYP2C19-mediated metabolizer groups may arise as a result of inter-individual variability, which potentially influences the efficacy and safety of escitalopram. Hence, it is crucial to establish a comprehensive collection of information relevant to each phenotype regarding the efficacy and tolerability of therapy. This will enable psychiatrists to make optimal decisions for individual patients. The aim of the study: The aim of this study is to classify MDD patients into various CYP2C19 metabolizer groups and to determine the association between phenotype and treatment outcome. Materials and Methods: The study enrolled 119 escitalopram monotherapy-treated MDD patients aged 18–58. MADRS, HDRS-17, and CGI were used to measure efficacy at baseline, weeks 4, 8, and 12. Safety and tolerability outcomes were examined from occurring ADRs. Clinical outcomes were compared among phenotypes based on changes in HDRS-17 and CGI scores from week 4 to week 12. Results: Subjects were categorized by CYP2C19 genotype: 20 poor (PM), 64 intermediate (IM), 24 extensive (EM), and 11 ultra-rapid (UM) metabolizers. Response and remission occurred in 67.2 % and 26.8 % of the 119 subjects at the end of the 12th week of the study. The response rate in PM was much lower (21.6 %) compared to EM. There were 312 adverse drug reactions (ADRs), and 88 (73.94 %) individuals had at least one. In safety data, nervousness was the most common ADR among the four groups 66 (55.4 %), followed by decreased appetite 48 (40.3 %). There were no severe ADRs. Men had more ADRs than women. Conclusion: CYP2C19 genotyping may help personalize escitalopram medication. The study found that the reduced ability of PM to metabolize escitalopram is probably associated with the decreased efficacy and tolerance shown in PM compared to EM and IM. The relationship between metabolizer status and treatment response followed the anticipated direction. Our findings should guide future clinical studies that include pharmacokinetic assessments


  • Open Access

    The impact of CYP2C19 genotypes on steady-state plasma concentration of escitalopram in South Indian population with Major Depressive Disorder

    by B. Jeevan Kumar, Vijayakumar Thangavel Mahalingam, Ganesh Kumar M

    Background: Among depressed patients, escitalopram plasma levels differed between those who were considered as extensive metabolizers and poor metabolizers of CYP2C19. However, the majority of research utilized the dose-response relationship. Consequently, we investigated the effect of variations in the CYP2C19 gene on the levels of drug in the bloodstream of individuals suffering from Major Depressive Disorder (MDD) in south India. Methods: A total of 109 individuals with MDD who were prescribed escitalopram at doses of 5, 10, 15, or 20 mg daily participated in this research. We used HPLC with SPD-10AVP UV-Visible detector to measure the escitalopram concentrations in the blood. The polymorphisms of the CYP2C19 were determined by employing the PCR techniques. Results: Our study found that 55% of the subjects were intermediate metabolizers, followed by extensive (19.3%), poor (17.4%), and ultra-rapid (8.3%). The significant correlation is identified between the steady state plasma concentration and Sex with (P - Value < 0.05), insignificant correlation was seen in Age and BMI with (P - Value > 0.05). The majority of gene variants seen in the study population were CYP2C19*1/*2, accounting for 49 individuals (44.9%). Conclusion: These findings showed that sex had a substantial impact on the CYP2C19 genetic variation. Medication administration to individuals with CYP2C19 PM requires special caution.


  • Open Access

    Safety and efficacy of LibidUp-PE supplement on premature ejaculation: A randomized, placebo-controlled double-blind, crossover study

    by Jagadeesan M, Adhisaya A, T. Srinivasan, Alphienes Stanley Xavier, Pavithra Anandan, Rajappan Chandra Satish Kumar, Thangavel Mahalingam Vijayakumar

  • Open Access

    Correction to: Pro-infammatory cytokine molecules from Boswellia serrate suppresses lipopolysaccharides induced infammation demonstrated in an in-vivo zebrafsh larval model

    by N. Sai Supra Siddhu, Ajay Guru, Rajappan Chandra Satish Kumar, Bader O. Almutairi, Mikhlid H. Almutairi, Annie Juliet, Thangavel Mahalingam Vijayakumar, Jesu Arockiaraj

  • Open Access

    Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis

    by Kaoshik Sureshkumar, Mahesh Durairaj, Kaviya Srinivasan, Khang Wen Goh, Krishna Undela, Vijayakumar Thangavel Mahalingam, Chrismawan Ardianto, Long Chiau Ming, Rajanandh Muhasaparur Ganesan

    Introduction: L-carnosine has been found to have multimodal activity. Aim: The aim of this review was to find out the efficacy of L-carnosine in patients with age-related diseases. Methods: Clinical studies evaluated the effect of L-carnosine on cancer, cardiovascular disease, diabetes, and neurodegenerative disorders were searched in electronic bibliographic databases. The protocol has been registered with PROSPERO (CRD42022314033). The revised Cochrane risk of bias tool for randomized trials was used to assess all of the reports for risk of bias. RevMan 5.4 was used to conduct the meta-analysis. Results: Following the screening process, 14 papers were selected for systematic review, with 9 of them being qualified for meta-analysis. Many of the included studies showed that L-carnosine has potential therapeutic activity in age related diseases. Results from the meta-analysis showed that in diabetes mellitus, HbA1c [mean difference (MD) 95% CI = –1.25 (–2.49, –0.022); p = 0.05; p = 0.001; I2 = 85%] and fasting blood sugar (FBS) [MD 95% CI = –12.44 (–22.44, –2.44); p = 0.01; p = 0.40; I2 = 0%] and in neurodegenerative disorder, Wechsler Memory Scale Logical Memory 2 (WMS-LM2) [MD 95% CI = 1.34 (0.83, 1.85); p < 0.00001; p = 0.43; I2 = 0%], showed statistically significant difference, favoring the L-carnosine group over the control group. While in neurodegenerative disorder, Alzheimer ’s Disease Assessment Scale (ADAS) [MD 95% CI = 0.98 (–1.55, –0.42); p = 0.0007; p = 0.86; I2 = 0%] and Back Depression Inventory (BDI) [MD 95% CI = –1.12 (–1.87, –0.37); p = 0.003; p = 0.73; I2 = 0%] showed statistically significant difference, favoring the control group over L-carnosine group. Conclusions: Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.


  • Pharmacogenetic Biomarkers and Personalized Medicine: Upcoming Concept in Pharmacotherapy

    by Navakanth Raju Ramayanam, Rajesh Nanda Amarnath, Thangavel Mahalingam Vijayakumar

    Pharmacogenomics is the study of an individual's response to drugs as a result of their genetic makeup. Pharmacogenomics has been merged with pharmacology and genomics to produce safe and effective drugs that are customized to the unique genetic profile of each individual. Drug prescribing focused on pharmacogenomics opens up a modern avenue for developing and prescribing safe and efficient drugs to specific patients. Patients that are prescribed medications that are more appropriate to them based on their physiology and lifestyle characteristics are referred to as obtaining personalized medicine. The medicinal use of molecularly targeted agents, which are commonly used for customized therapies, could aid in disease detection in a small number of patients. To assess the advantage of selected patients with genomic changes to a given treatment, clinical trial research designs for different diagnostics and therapeutics must aim for rate-limiting steps. Precision medicine techniques are used to classify specific patients' genetic flaws in the hopes of identifying new disease-prevention treatments. Precision medicine, on the other hand, is more precise in clinical practice, with an emphasis on identifying new therapeutic targets, recent advances in molecular testing trials, and a variety of advanced approaches are available for collecting biological samples in clinical practice to conduct genomic processing. Pharmacogenomics biomarkers use customized drugs to anticipate the incidence of diseases in the future. Individual precision medicine can overcome the limitations of traditional medicine in terms of disease prevention.


  • Open Access

    Functional and Structural Impact of Deleterious Missense Single Nucleotide Polymorphisms in the NR3C1, CYP3A5, and TNF-α Genes: An In Silico Analysis

    by Navakanth Raju Ramayanam, Ranjani Manickam, Vijayakumar Thangavel Mahalingam, Khang Wen Goh, Chrismawan Ardianto, Poovi Ganesan, Long Chiau Ming, Rajanandh Muhasaparur Ganesan

    Human diseases are generally influenced by SNPs (single nucleotide polymorphisms). The mutations in amino acid residues generated by deleterious SNPs contribute to the structural and functional diversity of the encoded protein. Tumor necrosis factor-α (TNF-α), Glucocorticoid receptor gene (NR3C1), and Cytochrome P450 3A5 (CYP3A5) play a key role in glucocorticoid resistance susceptibility in humans. Possible causative mutations could be used as therapeutic targets and diagnostic markers for glucocorticoid resistance. This study evaluated the missense SNPs of TNF-α, NR3C1, and CYP3A5 to predict their impact on amino acid changes, protein interaction, and functional stability. The protein sequence of dbSNP was obtained and used online in silico method to screen deleterious mutants for the in silico analysis. In the coding regions of TNF-α, NR3C1, and CYP3A5, 14 deleterious mutations were discovered. The protein functional and stability changes in the amino acid between native and mutant energy were identified by analyzing the changes in the hydrogen bonding of these mutants from native, which were all measured using Swiss PDB and PyMOL. F446S and R439K had the highest root-mean-square deviation (RMSD) values among the 14 deleterious mutants. Additionally, the conserved region of amino acid protein interaction was analyzed. This study could aid in the discovery of new detrimental mutations in TNF-α, NR3C1, and CYP3A5, as well as the development of long-term therapy for corticosteroid resistance in several inflammatory diseases. However, more research into the deleterious mutations of the TNF-α, NR3C1, and CYP3A5 genes is needed to determine their role in corticosteroid resistance.


  • Open Access

    A prospective study on prevalence of intradialytic complications and its management in the department of nephrology of tertiary care multispeciality teaching hospital

    by Jagadeesan M Jagadeesan M, Vijayakumar T M Vijayakumar T M

    Backround: Renal dysfunction has been more common during the last two decades, with an estimated 11-13 % prevalence. Hemodialysis is one of the most widely utilized medical procedures globally, with over two million patients undergoing regular hemodialysis yearly. Intradialytic complications are critical since they affect patients' quality of life, mortality, and morbidity. Therefore, it is important to monitor hemodialysis patients for complications during dialysis and understand the management strategy for various intradialytic complications. Methodology: prospective observational study conducted for the period of six months. Irespective of gender, age between 18-85 years with selected co-morbidities included in the study. Patients general demographic data, Personal history including adverse habits, occupation, food habits, also collected. All the collected data were evaluated with Microsoft Excel 2010, SPSS (v26.0), and GraphPad Prism software (V.8.2.0). Chi-Square test was utilized to determine the association between variables. Results: out of 245 patients, 30 (12.24 %) patients had intradialytic complications where 20 (66.67%) of them were male, and 10 (33.34%) were female. intradialytic complications like hypertension (HTN), Hypotension, Vomiting, Headache, shortness of breath were commonly found. Fever and vomiting were also present.